Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Veronika, Skalická"'
Autor:
Stanislava, Koloušková (AUTHOR), Veronika, Skalická (AUTHOR), Jana, Bartošová (AUTHOR), Jan, Lebl (AUTHOR)
Publikováno v:
Czecho-Slovak Pediatrics / Česko-Slovenská Pediatrie. 2023, Vol. 78 Issue 5, p258-260. 3p.
Autor:
Veronika Skalická
Publikováno v:
Časopis pro Právní Vědu a Praxi, Vol 28, Iss 3 (2020)
Recenze - ZAVRŠNIK, Aleš. Kyberkriminalita Praha: Wolters Kluwer ČR, 2017, 148 s. ISBN 978-80-7552-758-5.
Externí odkaz:
https://doaj.org/article/cef22ee5f62f49128ffb0338cd939a2b
Autor:
Eduard Jirkovský, Jan Korábečný, Tomáš Šimůnek, Anna Jirkovská, Veronika Skalická, Hana Bavlovič Piskáčková, Martin Štěrba, Jan Kubes, Iuliia Melnikova, Jaroslav Roh, Tomas Kucera, Caroline A. Austin, Josef Skoda, Lucie Nováková, Galina Karabanovich
Publikováno v:
Journal of Medicinal Chemistry. 64:3997-4019
Cardioprotective activity of dexrazoxane (ICRF-187), the only clinically approved drug against anthracycline-induced cardiotoxicity, has traditionally been attributed to its iron-chelating metabolite. However, recent experimental evidence suggested t
Autor:
Zuzana Pokorná, Tomáš Šimůnek, Petra Štěrbová-Kovaříková, Jan Kubes, Veronika Skalická, Jaroslav Roh, Yvona Mazurová, Olga Lenčová-Popelová, Petra Kollárová-Brázdová, Michaela Adamcova, Anna Jirkovská, Galina Karabanovich, Hana Bavlovič Piskáčková, Martin Štěrba, Eduard Jirkovský
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 373:402-415
Bisdioxopiperazine agent dexrazoxane (ICRF-187) has been the only effective and approved drug for prevention of chronic anthracycline cardiotoxicity. However, the structure-activity relationships (SARs) of its cardioprotective effects remain obscure
Autor:
Ferenc Karpati, L.E. Jenkins, D.M. Cox, Yvonne Belessis, Carla Federica Bortoluzzi, L. Da Dalt, Baroukh M. Assael, Ciro D'Orazio, Stéphanie Bui, V. Švabe, J.C. Dubus, L. Honková, A. Jung, Tanja Pressler, M. Geerdink, Phil Robinson, C. Vazquez, Rosaria Casciaro, Valeria Raia, A.J.M. Reid, C. Mainguy, Daan Caudri, Antonella Tosco, S. Rovira, M.C. Cavicchi, Eleonora Pontello, O. Sepe, Stephen M. Stick, A. Tai, Silvia Gartner, Paolo Rossi, M. G. Myriam Hunink, Veronika Skalická, Harm A.W.M. Tiddens, C.R. Hansen, A. Möller, Emily Pintani, Karin M. de Winter-de Groot, A.S. Neri, E. Rietschel, André Schultz, F. De Gregorio, Marijke Proesmans, F. Bremont, Paul Robinson
Publikováno v:
Journal of Cystic Fibrosis, 19(4), 641-646. Elsevier
Background Recent standards of care mention chest radiography (CR) but not chest computed tomography (CT) in routine annual follow-up of children with cystic fibrosis (CF). To minimise radiation risk, CT or CR should only be performed if they impact
Autor:
Eduard Jirkovský, Petra Kollárová-Brázdová, Alexander R. Lyon, Anna Jirkovská, Galina Karabanovich, Veronika Skalická, Olga Lenčová-Popelová, Michaela Adamcova, Jan Kubes, Petra Štěrbová-Kovaříková, Hana Bavlovic-Piskackova, Martin Štěrba, Jaroslav Roh, Zuzana Pokorná, Tomáš Šimůnek, Yvona Mazurová
Publikováno v:
Circulation. Heart failure. 14(11)
Background: Anthracycline-induced heart failure has been traditionally attributed to direct iron-catalyzed oxidative damage. Dexrazoxane (DEX)—the only drug approved for its prevention—has been believed to protect the heart via its iron-chelating
Autor:
Gert Fricker, Johanna J. Salomon, Veronika Skalická, Viktor Balzer, Dominik Witzigmann, Michael Binnefeld, Sandra Fritz, Hans-Ulrich Kauczor
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 153
Matrix-Liposomes (MLs) are a very promising solid oral drug delivery system; however, data on their interaction with biological membranes are not available. Here, we describe the quality of MLs manufactured by dual centrifugation. MLs were prepared w
Autor:
Petra, Kollárová-Brázdová, Anna, Jirkovská, Galina, Karabanovich, Zuzana, Pokorná, Hana, Bavlovič Piskáčková, Eduard, Jirkovský, Jan, Kubeš, Olga, Lenčová-Popelová, Yvona, Mazurová, Michaela, Adamcová, Veronika, Skalická, Petra, Štěrbová-Kovaříková, Jaroslav, Roh, Tomáš, Šimůnek, Martin, Štěrba
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 373(3)
Bisdioxopiperazine agent dexrazoxane (ICRF-187) has been the only effective and approved drug for prevention of chronic anthracycline cardiotoxicity. However, the structure-activity relationships (SARs) of its cardioprotective effects remain obscure
Autor:
E. Pokojová, M. Mala, Hana Vinohradská, P. Itterheimova, Pavel Drevinek, Veronika Skalická, Lukáš Homola, P. Kuban
Publikováno v:
Journal of Cystic Fibrosis. 20:S257
Autor:
Petra Brazdova, Petra Sterbova-Kovarikova, Jaroslav Roh, Hana Bavlovic-Piskackova, Michaela Adamcova, Zuzana Pokorná, Martin Sterba, Eduard Jirkovsky, Tomas Simunek, Veronika Skalická, Galina Karabanovich, Yvona Mazurová, Olga Lenčová-Popelová, Anna Jirkovská
Publikováno v:
Heart Failure.
Introduction Anthracyclines (ANT; e.g. doxorubicin, epirubucin or daunorubicin) are still indispensable part of modern chemotherapy regiments, despite of their well-known risk to induce cardiotoxicity leading even to heart failure. Thus, there is a n